Enterprise Therapeutics Publishes on Medicinal Chemistry of ETD001 | A Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis

The paper describes the medicinal chemistry optimisation of a new series of ENaC blockers, resulting in the invention of ETD001, Enterprise’s lead asset, a potential new inhaled treatment for cystic fibrosis notes Enterprise Therapeutics.